Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: The potential of 5-methyl-tetrahydrofolate

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 323-330

  Nzila, Alexis ^a   Okombo, John ^b   Molloy, Anne M ^c  

^a KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^b KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antifolate; Intermittent preventive treatment during pregnancy; IPTp; Neural tube defects; NTDs; Plasmodium falciparum

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FOLIC ACID; PYRIMETHAMINE PLUS SULFADOXINE;

AFRICA; DOSE RESPONSE; DRUG EFFICACY; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MALARIA CONTROL; NEURAL TUBE DEFECT; PLASMODIUM; PREGNANCY; PREGNANT WOMAN; REVIEW; VITAMIN SUPPLEMENTATION;

ANTIFOLATE; INTERMITTENT PREVENTIVE TREATMENT DURING PREGNANCY; IPTP; NEURAL TUBE DEFECTS; NTDS; PLASMODIUM FALCIPARUM;

ANENCEPHALY; ANIMALS; ANTIMALARIALS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATES; TREATMENT OUTCOME;

EID: 84892469646     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt394     Document Type: Review

References (61)

1. Dellicour S, Tatem AJ, Guerra CA et al. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 2010; 7: e1000221.
2. Rogerson SJ, Hviid L, Duffy PE et al. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007; 7: 105-17.
3. Desai M, ter Kuile FO, Nosten F et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7: 93-104.
4. Desai M, Dellicour S. Effects of malaria and its treatment in early pregnancy. Lancet Infect Dis 2012; 12: 359-60.
5. Uneke CJ, Ogbonna A. Malaria and HIV co-infection in pregnancy in sub-Saharan Africa: impact of treatment using antimalarial and antiretroviral agents. Trans R Soc Trop Med Hyg 2009; 103: 761-7.
6. Bardaji A, Bassat Q, Alonso PL et al. Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence. Expert Opin Pharmacother 2012; 13: 1719-36.
7. Menendez C, D'Alessandro U, ter Kuile FO. Reducing the burdenof malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007; 7: 126-35.
8. WHO Antenatal Care Trial Research Group. WHO Antenatal Care Randomized Trial: Manual for the Implementation of the New Model. 2002. http://www.who.int/reproductivehealth/publications/maternal_perinatal_ health/RHR_01_30/en/(3 June 2013, date last accessed).
9. van Eijk AM, Hill J, Alegana VA et al. Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data. Lancet Infect Dis 2011; 11: 190-207.
10. Gutman J, Kachur SP, Slutsker L et al. Combination of probenecidsulphadoxine- pyrimethamine for intermittent preventive treatment in pregnancy. Malar J 2012; 11: 39.
11. Abu-Saad K, Fraser D. Maternal nutrition and birth outcomes. Epidemiol Rev 2010; 32: 5-25.
12. de Onis M, Villar J, Gulmezoglu M. Nutritional interventions to prevent intrauterine growth retardation: evidence from randomized controlled trials. Eur J Clin Nutr 1998; 52 Suppl 1: S83-93.
13. Christianson A, Howson CP, Modell B. March of Dimes Global Report on Birth Defects: The Hidden Toll of Dying and Disabled Children. 2006. http://www.marchofdimes.com/glue/files/Birth_Defects_Report-PF.pdf (1 June 2013, date last accessed).
14. Daly LE, Kirke PN, Molloy A et al. Folate levels and neural tube defects. Implications for prevention. JAMA 1995; 274: 1698-702.
15. Blencowe H, Cousens S, Modell B et al. Folic acid to reduce neonatal mortality fromneural tubedisorders. Int J Epidemiol 2010;39Suppl 1: i110-21.
16. WolffT, Witkop CT, Miller T et al. Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150: 632-9.
17. Botto LD, Moore CA, Khoury MJ et al. Neural-tube defects. N Engl J Med 1999; 341: 1509-19.
18. Mosley BS, Hobbs CA, Flowers BS et al. Folic acid and the decline in neural tube defects in Arkansas. J Ark Med Soc 2007; 103: 247-50.
19. Chandler AL, Hobbs CA, Mosley BS et al. Neural tube defects and maternal intake of micronutrients related to one-carbon metabolism or antioxidant activity. Birth Defects Res A Clin Mol Teratol 2012; 94:864-74.
20. Sa JM, Chong JL, Wellems TE. Malaria drug resistance:newobservations and developments. Essays Biochem 2011; 51: 137-60.
21. Nzila A, Ward SA, Marsh K et al. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 2005; 21: 292-8.
22. Kelly P, McPartlin J, Goggins M et al. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 1997; 65: 1790-5.
23. Nzila A. The past, present and future of antifolates in the treatment of Plasmodiumfalciparuminfection. JAntimicrobChemother2006;57:1043-54.
24. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009; 7: 999-1013.
25. Sridaran S, McClintock SK, Syphard LM et al. Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J 2010; 9: 247.
26. Oyibo WA, Agomo CO. Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. Matern Child Health J 2011; 15: 542-52.
27. Chico RM, Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Trop Med Int Health 2011; 16: 774-85.
28. Briand V, Bottero J, Noel H et al. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 2009; 200: 991-1001.
29. Cisse B, Cairns M, Faye E et al. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 2009; 4: e7164.
30. Kinyanjui SM, Mberu EK, Winstanley PA et al. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am J Trop Med Hyg 1999; 60: 943-7.
31. Nduati E, Diriye A, Ommeh S et al. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res 2008; 102: 1227-34.
32. Metz J. Folic acid metabolism and malaria. Food Nutr Bull 2007; 28:S540-9.
33. Wang P, Sims PF, Hyde JE. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance. Parasitology 1997; 115: 223-30.
34. Watkins WM, Mberu EK, Winstanley PA et al. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997;13: 459-64.
35. Sirotnak FM, Moccio DM, Young CW. Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux. Cancer Res 1981;41: 966-70.
36. Sirotnak FM, Wendel HG, Bornmann WG et al. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res 2000; 6: 3705-12.
37. Nzila A, Mberu E, Bray P et al. Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother 2003; 47:2108-12.
38. Salcedo-Sora JE, Ochong E, Beveridge S et al. The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters. J Biol Chem 2011; 286: 44659-68.
39. Wang P, Wang Q, Sims PF et al. Characterisation of exogenous folate transport in Plasmodium falciparum. Mol Biochem Parasitol 2007; 154:40-51.
40. Sowunmi A, Adedeji AA et al. Comparative effects of pyrimethaminesulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria. Ann Trop Med Parasitol 2004; 98: 873-8.
41. Sowunmi A, Fehintola FA, Adedeji AA et al. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop Med Int Health 2004; 9: 606-14.
42. vanHensbroek MB, Morris-Jones S, Meisner S et al. Iron, but not folicacid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89: 672-6.
43. Carter JY, Loolpapit MP, Lema OE et al. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg 2005; 73: 166-70.
44. Mulenga M, Malunga P, Bennett S et al. Folic acid treatment of Zambian children with moderate to severe malaria anemia. AmJ Trop Med Hyg 2006;74: 986-90.
45. Barton V, Fisher N, Biagini GA et al. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol 2010; 14: 440-6.
46. Dzinjalamala FK, Macheso A, Kublin JG et al. Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 2005;72: 267-72.
47. Ouma P, Parise ME, Hamel MJ et al. A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine. PLoS Clin Trials 2006; 1: e28.
48. van Eijk AM, Ouma PO, Williamson J et al. Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western Kenya who have uncomplicated malaria. J Infect Dis 2008; 198: 1550-3.
49. Mbaye A, Richardson K, Balajo B et al. Lack of inhibition of the antimalarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae. Am J Trop Med Hyg 2006; 74: 960-4.
50. Loria P, Miller S, Foley M et al. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem J 1999; 339: 363-70.
51. Martin RE, Kirk K. Transport of the essential nutrient isoleucine inhuman erythrocytes infected with the malaria parasite Plasmodium falciparum. Blood 2007; 109: 2217-24.
52. Cobbold SA, Martin RE, Kirk K. Methionine transport in the malaria parasite Plasmodium falciparum. Int J Parasitol 2011; 41: 125-35.
53. Asawamahasakda W, Yuthavong Y. The methionine synthesis cycle and salvage of methyltetrahydrofolate from host red cells in the malaria parasite (Plasmodium falciparum). Parasitology 1993; 107: 1-10.
54. Obeid R, Holzgreve W, Pietrzik K. Is 5-methyltetrahydrofolate an alternative to folic acid for the prevention of neural tube defects? J Perinat Med 2013; 41: 469-83.
55. Pietrzik K, Bailey L, Shane B. Folic acid and L-5-methyltetrahydro-folate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2010; 49: 535-48.
56. Wright AJ, Dainty JR, Finglas PM. Folic acid metabolism in human subjects revisited: potential implications for proposed mandatory folic acid fortification in the UK. Br J Nutr 2007; 98: 667-75.
57. Bostom AG, Shemin D, Bagley P et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000; 101: 2829-32.
58. Bailey SW, Ayling JE. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci USA 2009; 106: 15424-9.
59. Babior BM. Chapter 37, The Megaloblastic Anemias. http://medtextfree. wordpress.com/2011/12/27/chapter-37-the-megaloblastic-anemias/(1 June 2013, date last accessed).
60. Wald NJ, Law MR, Morris JK et al. Quantifying the effect of folic acid. Lancet 2001; 358: 2069-73.
61. Houghton LA, Sherwood KL et al. [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr 2006; 83: 842-50.